All Stories

  1. Electrochemotherapy as Promising Treatment Option in Rare Recurrent Cutaneous Neoplasm of the Scalp: Case Report of an Elderly Patient

    Article • Case Reports in Oncological Medicine, March 2019, Hindawi Publishing Corporation

    Prof. Paolo Marchetti, MICHELA ROBERTO

  2. Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice

    Article • Analytical Cellular Pathology, January 2018, Hindawi Publishing Corporation

    Prof. Paolo Marchetti, Sabatino Valente

  3. Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients

    Article • Pharmacogenomics, June 2017, Future Medicine

    Prof. Paolo Marchetti

  4. PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?

    Article • BioMed Research International, January 2017, Hindawi Publishing Corporation

    Giulia d'Amati, Prof. Paolo Marchetti, Giuseppe Naso

  5. Bevacizumab in breast cancer

    Article • Future Oncology, November 2016, Future Medicine

    Prof. Paolo Marchetti, Professor Fabio Puglisi, Fabio Puglisi

  6. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment

    Article • Oncotarget, October 2016, Impact Journals, LLC

    Prof. Paolo Marchetti

  7. Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients

    Article • Future Oncology, September 2016, Future Medicine

    Prof. Paolo Marchetti

  8. Bevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons

    Article • Tumori Journal, September 2016, SAGE Publications

    Prof. Paolo Marchetti

  9. Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation

    Article • OncoTargets and Therapy, November 2013, Taylor & Francis

    Dr Angelo Zullo, Prof. Paolo Marchetti

  10. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

    Article • ClinicoEconomics and Outcomes Research, April 2013, Taylor & Francis

    Prof. Paolo Marchetti